Orphan status for pancreatic cancer treatment

The European Commission has just granted Orphan drug status to the BL-8040 (Motixafortide) pancreatic cancer treatment from Israel’s BioLineRX (see here). BioLineRX can now receive benefits including EU funding, less regulation, and market exclusivity.

https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-receives-orphan-drug-designation-motixafortide-bl-8040

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *